Polycystic ovary syndrome
- PMID: 9429864
- DOI: 10.1016/s0889-8529(05)70286-3
Polycystic ovary syndrome
Abstract
The cardinal clinical features of PCOS are hirsutism and menstrual irregularity from anovulation. Obesity occurs in approximately 50% of hyperandrogenic anovulatory women, some of whom also have non-insulin-dependent diabetes mellitus. Underlying these clinical findings are several biochemical abnormalities, including LH hypersecretion, hyperandrogenism, acyclic estrogen production, decreased SHBG capacity, and hyperinsulinemia, all of which contribute to increased ovarian production of androgens, particularly T. A fundamental mechanism of ovarian hyperandrogenism in PCOS is LH hypersecretion. Whether the central nervous system is a possible locus for initiating LH hypersecretion remains unclear, because exaggerated LH secretion is temporarily reversed by induced ovulatory cycles or physiologic luteal concentrations of progesterone. On the other hand, desynchronization of pulsatile LH secretion from sleep in girls with PCOS and an exaggerated (e.g., masculinized) early LH response to GnRHa testing in women with hyperandrogenic anovulation and congenital adrenal virilizing disorders suggest that events occurring before puberty, perhaps during fetal life, may irreversibly alter neuroendocrine function. Hyperinsulinemia from insulin resistance is an important regulatory mechanism governing ovarian hyperandrogenism. Hyperinsulinemia in hyperandrogenic anovulatory women potentiates ovarian hyperandrogenism by enhancing LH secretion; potentiating 17-hydroxylase and, to a lesser extent, 17,20-lyase activity; and suppressing SHBG capacity. It is a key component of hyperandrogenic anovulation caused by a type of insulin resistance that in independent and additive to that of obesity alone. Although the mechanisms governing insulin action on ovarian steroidogenesis are unknown, abnormalities of intracellular insulin signaling or cytochrome P450c 17[alpha] activity may render the 17-hydroxylase/17,20-lyase enzyme complex more sensitive to insulin. Hyperinsulinemia in hyperandrogenic anovulatory women is accompanied by upper-body obesity characterized by an increased amount of abdominal fat. Upper-body obesity is an important independent risk factor for CVD and diabetes. Although genetic and environmental factors affect fat distribution, sex steroids, particularly androgens, regulate lipid metabolism, suggesting yet another link between the hormonal and metabolic abnormalities of hyperandrogenic anovulation. A careful history and physical examination guide the extent of diagnostic testing. Slowly progressive hirsutism with anovulation of peripubertal onset usually reflects hyperandrogenic anovulation. This type of clinical presentation requires an evaluation to rule out other endocrinopathies (e.g., virilizing tumors, adult-onset CAH, hyperprolactinemia, and Cushing's syndrome). Virilization or severe rapidly progressive hirsutism requires immediate investigation to rule out a possible virilizing tumor. The ultimate goals of therapy for hyperandrogenic anovulatory women are to normalize the endometrium, antagonize androgen action at target tissues, reduce insulin resistance, and correct anovulation, if necessary.
Similar articles
-
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.Endocr Pract. 2015 Nov;21(11):1291-300. doi: 10.4158/EP15748.DSC. Endocr Pract. 2015. PMID: 26509855
-
Menstrual disorders in adolescents. Excess androgens and the polycystic ovary syndrome.Pediatr Clin North Am. 1999 Jun;46(3):519-43. doi: 10.1016/s0031-3955(05)70135-8. Pediatr Clin North Am. 1999. PMID: 10384805 Review.
-
Polycystic Ovary Syndrome.Obstet Gynecol. 2018 Aug;132(2):321-336. doi: 10.1097/AOG.0000000000002698. Obstet Gynecol. 2018. PMID: 29995717 Review.
-
Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.Arch Gynecol Obstet. 2006 Jul;274(4):227-32. doi: 10.1007/s00404-006-0173-8. Epub 2006 May 12. Arch Gynecol Obstet. 2006. PMID: 16691383
-
Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.Treat Endocrinol. 2006;5(3):171-87. doi: 10.2165/00024677-200605030-00005. Treat Endocrinol. 2006. PMID: 16677059
Cited by
-
The Polycystic Ovary Syndrome Quality of Life scale (PCOSQOL): Development and preliminary validation.Health Psychol Open. 2018 Jul 19;5(2):2055102918788195. doi: 10.1177/2055102918788195. eCollection 2018 Jul-Dec. Health Psychol Open. 2018. PMID: 30038788 Free PMC article.
-
Integrated Computational Approaches for Inhibiting Sex Hormone-Binding Globulin in Male Infertility by Screening Potent Phytochemicals.Life (Basel). 2023 Feb 9;13(2):476. doi: 10.3390/life13020476. Life (Basel). 2023. PMID: 36836833 Free PMC article.
-
Polycystic ovary syndrome in adolescents: current and future treatment options.Paediatr Drugs. 2006;8(5):311-8. doi: 10.2165/00148581-200608050-00004. Paediatr Drugs. 2006. PMID: 17037948 Review.
-
The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome.Drugs. 2009 Jul 30;69(11):1417-31. doi: 10.2165/00003495-200969110-00001. Drugs. 2009. PMID: 19634921 Review.
-
Specific Alteration of Branched-Chain Amino Acid Profile in Polycystic Ovary Syndrome.Biomedicines. 2023 Jan 1;11(1):108. doi: 10.3390/biomedicines11010108. Biomedicines. 2023. PMID: 36672616 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous